"Many areas of life science research, including biomarker discovery and drug development, involve measurements of DNA, RNA, and proteins. Analyzing these different types of biomolecules typically requires three separate platforms. However, the simultaneous digital quantification enabled by our 3D
Biology™ approach addresses many of the challenges inherent in sequential testing," said
"This year's crop of Top 10 Innovation submissions contained some great products that posed a real challenge to our panel of experts, tasked by us with singling out the best and brightest," said Editor-in-Chief
For more information about The Scientist's Top 10 Innovations 2016 and for a full list of winners, visit: www.the-scientist.com/2016Top10.
This is the second time in recent years that one of NanoString's products has been honored as a Top 10 Innovation. In 2013, The Scientist also listed NanoString's Prosigna® Breast Cancer Prognostic Gene Signature Assay in the Top 10 Innovations list. The Prosigna Assay assesses a patient's risk of distant breast cancer recurrence at 10 years in postmenopausal women with node-negative (Stage I or II), or node-positive (Stage II), hormone receptor-positive breast cancer by examining the gene expression profile of the patient's tumor cells.
For more information, please visit www.nanostring.com.
The NanoString Technologies logo, NanoString, NanoString Technologies, nCounter, 3D Biology, and Prosigna are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.
Doug FarrellVice President, Investor Relations & Corporate Communications email@example.com Phone: 206-602-1768
News Provided by Acquire Media